Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine

US10633451B2 · kind B2 · utility

Assignees

• Hoffmann-La Roche Inc. · US
• Ludwig-Maximilians-Universitat Munchen · DE

Inventors

• Carole Bourquin · Belfaux, CH
• Raffaella Castoldi · Munich, DE
• Stefan Endres · Munich, DE
• Christian Klein · Iffeldorf, DE
• Sebastian Kobold · Munich, DE
• Gerhard Niederfellner · Oberhausen, DE
• Claudio Sustmann · Munich, DE

Key dates

• Filing date: Jan 24, 2013
• Grant date: Apr 28, 2020
• Expiry date: Feb 25, 2034

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02P20/582
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a bispecific (monoclonal) antibody molecule with a first binding domain binding an antigen on CD8+ T-cells that does not naturally occur in and/or on CD8+ T-cells and a second binding domain binding to a tumor specific antigen naturally occurring on the surface of a tumor cell. The bispecific (monoclonal) antibody molecules are particularly useful in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor. The invention provides the use of said (bispecific) antibody molecules as a medicament, the (bispecific) antibody molecules for use in a method for the treatment of particular diseases as well as a pharmaceutical composition/medicament comprising said (bispecific) antibody molecules, wherein said (bispecific) antibody molecules are to be administered in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor in a specific treatment regimen. Further aspects of the invention are nucleic acid sequences encoding said bispecific (monoclonal) antibody molecules, vectors.host cel…